These reformulated drugs can also be tested for use in other diseases such as psoriasis, inflammatory bowel disease, rheumatoid arthritis, and ankylosing spondylitis, where non-selective TNF alpha-blockers have been approved but their use is limited due to demyelinating side effects. Here, TNF is linked to psoriasis.